Clinical Trial Update: Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing intramuscular versus subcutaneous administration of long-acting Pamorelin (triptorelin) shows equivalence for treating prostate cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Long Acting Pamorelin 11.25 mg (triptorelin)

Snippet

Sponsor: Ipsen | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-05-26